Clinical trial
Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in…
NCT00311753 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00311753 |
|---|---|
| Title | Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients |
| Official title | An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Embolism |
| Intervention type | Drug |
| Interventions | Certoparin, Heparin |
| Enrollment | 342 |
| Start date | Feb 1, 2006 |
| Primary completion | Dec 1, 2007 |
| First posted | Apr 6, 2006 |
| Last update posted | Feb 24, 2017 |
| Countries | Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: